Claims:

1. A stabilised polymeric silicate liquid composition for use in therapy, wherein the silicate composition comprises polymeric silicic acid and nanosilicate particles having mean diameters of 20 nm or less and wherein the silicate composition is aquated and comprises a stabilising agent that comprises a polyalkylene glycol and/or a sugar in which the stabilising agent inhibits formation of condensed silicates, and wherein the composition is as obtainable by a process comprising the steps of:

(a) providing an aqueous solution of a soluble silicate at a pH greater than or equal to 9.5;

(b) reducing the pH of the silicate solution to cause polymerisation of the silicate to form polymeric silicic acid and nanosilicate particles; and

(c) simultaneously or sequentially with steps (a) and/or (b) adding to the silicate solution a stabilising agent that comprises a polyalkylene glycol and/or a sugar thereby producing a stabilised silicate composition in which the stabilising agent inhibits formation of condensed silicates;

wherein the stabilised polymeric silicate composition is aquated and wherein the process does not involve drying the composition or heating it above 100°C.

2. The stabilised polymeric silicate liquid composition for use in therapy according to claim 1, wherein the composition is formulated for parenteral administration.

3. The stabilised polymeric silicate liquid composition for use in therapy according to claim 2, wherein the parenteral administration is intravenous (IV), intraperitoneal (IP) or intramuscular (IM) administration.

4. The stabilised polymeric silicate liquid composition for use in therapy according to claim 3, wherein the parenteral administration is intravenous (IV) administration via an intravenous drip.

5. The stabilised polymeric silicate liquid composition for use in therapy according to any one of the preceding claims, wherein the composition is diluted or neutralised to a physiologically acceptable pH for administration.

6. The stabilised polymeric silicate composition for use in therapy according to any one of the preceding claims, wherein the pH is between 3.0 and 9.0.

7. The stabilised polymeric silicate composition for use in therapy according to any one of the preceding claims, wherein the composition has a concentration of silicon of 2.5mM or more, 5.0mM or more, 25mM or more, or 40mM or more.

8. The stabilised polymeric silicate composition for use in therapy according to any one of the preceding claims, wherein the composition is for treating a human subject.

9. The stabilised polymeric silicate composition for use in therapy according to any one of claims 1 to 7, wherein the composition is for veterinary administration.

10. The stabilised polymeric silicate composition for use in therapy according to any one of the preceding claims, wherein the therapy is the treatment of osteoporosis, osteopenia, musculoskeletal and joint disorders, cancer, skin conditions, vascular diseases, cardiovascular diseases, coronary heart diseases, inflammatory diseases, autoimmune diseases, Alzheimer's disease, cognitive impairment, infections, wounds , ulcers, gastrointestinal disorders, liver disease, kidney disease, immune related disorders or hormone related disorders.

11. The stabilised polymeric silicate composition for use in therapy according to any one of claims 1 to 10, wherein the composition is for oral delivery to bind cations in the gut, such as iron.

12. The stabilised polymeric silicate composition for use in therapy according to any one of claims 1 to 10, wherein the composition is for intravenous delivery for the treatment of cancer.

13 The stabilised polymeric silicate composition for use in therapy according to any one of claims 1 to 10, wherein the composition is for intravenous delivery for the treatment of infections.

14. Use of a stabilised polymeric silicate composition in the manufacture of a medicament for promoting wound healing and/or treating or preventing bacterial infection, wherein the silicate composition comprises polymeric silicic acid and nanosilicate particles having mean diameters of 20 nm or less and a stabilising agent comprising a polyalkylene glycol, and wherein the composition is formulated as a cream or an ointment for topical administration, and wherein the composition is as obtainable by a process comprising the steps of:

(a) providing an aqueous solution of a soluble silicate at a pH greater than or equal to 9.5;

(b) reducing the pH of the silicate solution to cause polymerisation of the silicate to form polymeric silicic acid and nanosilicate particles; and

(c) simultaneously or sequentially with steps (a) and/or (b) adding to the silicate solution a stabilising agent that comprises a polyalkylene glycol and/or a sugar thereby producing a stabilised silicate composition in which the stabilising agent inhibits formation of condensed silicates;

wherein the stabilised polymeric silicate composition is aquated and wherein the process does not involve drying the composition or heating it above 100°C.

15. The use of a stabilised polymeric silicate composition according to claim 14, wherein the polyalkylene glycol is polyethylene glycol (PEG).

16. The use of a stabilised polymeric silicate composition for according to claim 14 or claim 15, wherein the pH is between 3.0 and 9.0.

17. The use of a stabilised polymeric silicate composition for according to claim 14 or claim 15, wherein the composition has a concentration of silicon of 2.5mM or more, 5.0mM or more, 25mM or more, or 40mM or more.

18. The use of a stabilised polymeric silicate composition for according to claim 14 or claim 15, wherein the composition is for treating a human subject.

19. The use of a stabilised polymeric silicate composition for according to claim 14 or claim 15, wherein the composition is for

20. A silicate-containing supplement comprising a stabilised polymeric silicate composition comprising polymeric silicic acid and nanosilicate particles having mean diameters of 20 nm or less for use in the delivery of silicic acid to a human or animal subject, wherein the composition is in the form of a liquid filled capsule and comprises a stabilising agent that comprises a polyalkylene glycol and/or a sugar in which the stabilising agent inhibits formation of condensed silicates, wherein the composition is as obtainable by a process comprising the steps of:

(a) providing an aqueous solution of a soluble silicate at a pH greater than or equal to 9.5;

(b) reducing the pH of the silicate solution to cause polymerisation of the silicate to form polymeric silicic acid and nanosilicate particles; and

(c) simultaneously or sequentially with steps (a) and/or (b) adding to the silicate solution a stabilising agent that comprises a polyalkylene glycol and/or a sugar thereby producing a stabilised silicate composition in which the stabilising agent inhibits formation of condensed silicates;

wherein the stabilised polymeric silicate composition is

aquated and wherein the process does not involve drying the composition or heating it above 100°C.

21. The silicate-containing supplement of claim 20, wherein the composition is for direct oral administration.

22. Use of a stabilised polymeric silicate composition in the manufacture of a medicament for the treatment of osteoporosis, osteopenia, musculoskeletal and joint disorders, cancer, skin conditions, vascular diseases, cardiovascular diseases, coronary heart diseases, inflammatory diseases, autoimmune diseases, Alzheimer's disease, cognitive impairment, infections, wounds , ulcers, gastrointestinal disorders, liver disease, kidney disease, immune related disorders or hormone related disorders, wherein the silicate composition comprises polymeric silicic acid and nanosilicate particles having mean diameters of 20 nm or less and wherein the silicate composition is aquated and comprises a stabilising agent that comprises a polyalkylene glycol and/or a sugar in which the stabilising agent inhibits formation of condensed silicates, and wherein the composition is as obtainable by a process comprising the steps of:

(a) providing an aqueous solution of a soluble silicate at a pH greater than or equal to 9.5;

(b) reducing the pH of the silicate solution to cause polymerisation of the silicate to form polymeric silicic acid and nanosilicate particles; and

(c) simultaneously or sequentially with steps (a) and/or (b) adding to the silicate solution a stabilising agent that comprises a polyalkylene glycol and/or a sugar thereby producing a stabilised silicate composition in which the stabilising agent inhibits formation of condensed silicates;

wherein the stabilised polymeric silicate composition is aquated and wherein the process does not involve drying the composition or heating it above 100°C.

23. The use of a stabilised polymeric silicate composition according to claim 22, wherein) the composition is for oral delivery to bind cations in the gut, such as iron.

24. The use of a stabilised polymeric silicate composition according to claim 22, wherein the composition is for intravenous delivery for the treatment of cancer.

25. The use of a stabilised polymeric silicate composition according to claim 22, wherein the composition is for intravenous delivery for the treatment of infections.